Strategic Gateway · MENA Healthcare

Accelerating access.
Amplifying growth.

Kayastha Life Sciences connects science, strategy and distribution — building the commercial and operational bridge between global pharmaceutical innovation and high-growth demand across the UAE and GCC.

Our Journey Meet the Group
UAE
Regional Headquarters
5+
Group Companies
6
Therapy Segments
2
Global Brand Mandates
Our Story · Momentum

Built on science. Scaled through strategy.

Kayastha Life Sciences operates as a marketing company and scientific office, working in strategic partnership with GenQore — and has since scaled its footprint into distribution, international brand mandates and, now, end-to-end digital operations across the region.

'26 · Expansion — from marketing office to regional distributor
Distribution

Acquired Shifa Medico

Extending the group into pharmaceutical distribution and warehousing across the UAE.

Brand Mandate · Spain

Wellbiotic — Sales & Marketing

Secured the sales and marketing mandate for the Wellbiotic gut-health portfolio.

Brand Mandate

Atlyn Pharma — Sales & Marketing

A new specialty and general medicine portfolio brought to the region.

Strategic Partner · Operations

Influx Healthtech

Named strategic partner for end-to-end operations across the MENA region, digitizing the group's supply chain and field infrastructure.

The Group

One ecosystem, five disciplines.

Each entity plays a distinct role in the value chain — from science to shelf to system — so that every brand we carry moves faster and lands stronger.

01
Marketing Co. · Scientific Office

Kayastha Life Sciences

The group's strategic core — setting direction, medical affairs and market access strategy across all group companies.

02
Strategic Marketing Partner

GenQore

Strategic partner for field execution, sales-force deployment and go-to-market strategy across the UAE.

03
Distribution · Acquired 2026

Shifa Medico

Pharmaceutical distribution and warehousing network, acquired in 2026 to extend the group's reach to pharmacy shelf.

04
Brand Mandate · Spain

Wellbiotic

Sales and marketing rights acquired in 2026 for the Wellbiotic nutraceutical and gut-health portfolio.

05
Brand Mandate

Atlyn Pharma

Sales and marketing rights acquired in 2026, broadening the group's specialty and general medicine portfolio.

06
Technology & Operations · 2026

Influx Healthtech

Strategic partner for end-to-end operations across the MENA region — the digital backbone connecting supply chain, field data and distribution.

Therapeutic Portfolio

Nine segments. One patient-first standard.

Our commercial teams cover a deliberately broad footprint — built to serve both primary care and specialty channels.

🩺

General Medicine

Broad primary-care coverage across UAE hospitals, clinics and community pharmacies.

🧠

Psychiatry

Specialty engagement with mental-health practitioners and institutional formularies.

🫁

RTI

Respiratory tract infection therapies supporting seasonal and year-round patient demand.

🌿

Gut Health

Probiotic and digestive-health solutions, anchored by the Wellbiotic portfolio.

💊

Nutraceuticals

Preventive and wellness-focused supplement lines for retail and pharmacy channels.

🍃

Herbal Medicines

Traditional and plant-based therapies positioned for a growing regional wellness market.

❤️

Cardio-Diabetic

Cardiovascular and metabolic care spanning hypertension, lipid management and diabetes therapy.

🧬

Neurology

Specialty support for neurological conditions, built around hospital and specialist networks.

🦴

Ortho

Orthopaedic and musculoskeletal therapies serving surgeons, physiotherapists and trauma care.

Partnerships

Powered by shared expertise.

Kayastha Life Sciences leverages a network of specialist partners across the pharmaceutical value chain.

GenQore
Strategic Marketing
Shifa Medico
Distribution
Wellbiotic
Gut Health · Spain
Atlyn Pharma
Specialty Portfolio
Influx Healthtech
End-to-End Operations · MENA